Back to Agenda
Proprietary Name Review: International Perspectives from the FDA, Health Canada, and EMA
Session Chair(s)
Lina AlJuburi, PHARMD, MSC
Head, Regulatory Science and Policy, North America, Sanofi, United States
A trademark that minimizes the risk for medication errors is important to all stakeholders. Learning the role of trademarks and review is critical to the success of the process. An international panel of regulators will discuss the approach they take.
Learning Objective : Discuss trademark development and review processes; Identify the important role of trademarks; Assess take-away points to improve internal company processes.
Speaker(s)
Kellie Taylor
Associate Director, OMEPRM, OSE, CDER, FDA, FDA, United States
FDA Perspective
Cathy A. Parker
Director General, Biologics & Genetic Therapies Directorate HPFB, Health Canada, Canada
Health Canada's Revised Guidance For Industry: Review of Brand Names Past, Present, and Future
Isabelle Moulon, MD
Head of Patients and Healthcare Professionals Department, European Medicines Agency, Netherlands
EMA Perspective
Have an account?